It’s about big picture strategy and priorities, not personnel. An advocate of one approach leaves and his replacement has a different approach. This neither unusual nor is it a complicated concept.
More that their cell-based therapy guy leaving corresponds to a general shift in strategy away from cell-based therapies. They're more focused on antibody-based immunotherapy, particularly their bispecifics.
Market Data 
Markets 
